On Monday, Akebia Therapeutics Inc (NASDAQ: AKBA) opened higher 9.47% from the last session, before settling in for the closing price of $1.69. Price fluctuations for AKBA have ranged from $0.80 to $2.48 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 5.16%. Company’s average yearly earnings per share was noted 13.10% at the time writing. With a float of $199.72 million, this company’s outstanding shares have now reached $210.29 million.
Considering the fact that the conglomerate employs 167 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 61.9%, operating margin of -20.21%, and the pretax margin is -23.18%.
Akebia Therapeutics Inc (AKBA) Insider Activity
A key investor’s attitude towards the stock of the Drug Manufacturers – Specialty & Generic industry is another important factor to consider. The insider ownership of Akebia Therapeutics Inc is 5.03%, while institutional ownership is 24.14%. The most recent insider transaction that took place on May 13 ’24, was worth 15,140. In this transaction SVP, Chief Legal Officer of this company sold 12,016 shares at a rate of $1.26, taking the stock ownership to the 651,243 shares. Before that another transaction happened on May 13 ’24, when Company’s SVP, Chief Operating Officer sold 34,840 for $1.26, making the entire transaction worth $43,898. This insider now owns 672,092 shares in total.
Akebia Therapeutics Inc (AKBA) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 6/30/2024, the company posted -0.08 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.08) by 0. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.05 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 13.10% per share during the next fiscal year.
Akebia Therapeutics Inc (NASDAQ: AKBA) Trading Performance Indicators
Check out the current performance indicators for Akebia Therapeutics Inc (AKBA). In the past quarter, the stock posted a quick ratio of 0.82. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.27.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.20, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.26 in one year’s time.
Technical Analysis of Akebia Therapeutics Inc (AKBA)
Compared to the last year’s volume of 3.13 million, its volume of 2.59 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 87.78%. Additionally, its Average True Range was 0.09.
During the past 100 days, Akebia Therapeutics Inc’s (AKBA) raw stochastic average was set at 100.00%, which indicates a significant increase from 100.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 80.86% in the past 14 days, which was higher than the 72.62% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.4339, while its 200-day Moving Average is $1.3907. Nevertheless, the first resistance level for the watch stands at $1.9000 in the near term. At $1.9500, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.0500. If the price goes on to break the first support level at $1.7500, it is likely to go to the next support level at $1.6500. Should the price break the second support level, the third support level stands at $1.6000.
Akebia Therapeutics Inc (NASDAQ: AKBA) Key Stats
There are currently 210,288K shares outstanding in the company with a market cap of 396.07 million. Presently, the company’s annual sales total 194,620 K according to its annual income of -51,930 K. Last quarter, the company’s sales amounted to 43,650 K and its income totaled -8,580 K.
